Emmaus Life SciencesEMMA -0.02% EPS without NRI is $-0.12 as of Mar. 2026. The stock has 6 warning signs investors should review. Among 1,172 Biotechnology companies, Emmaus Life Sciences ranks better than 58.53% on this metric.
Emmaus Life Sciences's earnings per share without non-recurring items for the
three
months ended in Mar. 2026 was $-0.05.
Its earnings per share without non-recurring items for the trailing twelve months (TTM) ended in Mar. 2026 was $-0.12.
During the past 3 years, the average earnings per share (NRI) Growth Rate was 23.50% per year.
During the past 5 years, the average earnings per share (NRI) Growth Rate was 7.30% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using Earnings per share without Non-Recurring Items (NRI) data.
The historical rank and industry rank for Emmaus Life Sciences's EPS without NRI or its related term are showing as below:
EMMA'
s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: -545.8 Med: 20.4 Max: 81.7
Current: 23.5
During the past 13 years, Emmaus Life Sciences's highest 3-Year average Earnings Per Share (NRI) Growth Rate was 81.70% per year. The lowest was -545.80% per year. And the median was 20.40% per year.
EMMA's 3-Year EPS without NRI Growth Rate is ranked better than 58.53% of 1172
companies
in the Biotechnology industry
Industry Median: 16.8
vs EMMA: 23.50
Emmaus Life Sciences's EPS (Basic) for the
three
months ended in Mar. 2026 was $-0.05.
Its EPS (Basic) for the trailing twelve months (TTM) ended in Mar. 2026 was $-0.13.
Emmaus Life Sciences (OTCPK:EMMA) EPS without NRI Explanation
EPS without NRI removes onetime and unusual items from EPS, to provide investors with a more accurate measure of the company’s true earnings. The earnings are adjusted for items that are irregular or unusual in nature, and/or are non-recurring. This is calculated using Net Income (Continuing Operations) plus/minus any tax affected unusual Items and Goodwill Impairments/Write Offs. This can be used to fairly measure a company's profitability.
Be Aware
Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.
If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.
Emmaus Life Sciences EPS without NRI Related Terms
Emmaus Life Sciences EPS without NRI Historical Data
* Premium members only.
The historical data trend for Emmaus Life Sciences's EPS without NRI can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
EMMA vs PTIX, BZYR, RMTG: EPS without NRI Comparison
For the Biotechnology subindustry, Emmaus Life Sciences's PE Ratio without NRI, along with its competitors' market caps and PE Ratio without NRI data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Emmaus Life Sciences PE Ratio without NRI vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Emmaus Life Sciences's PE Ratio without NRI distribution charts can be found below:
* The bar in red indicates where Emmaus Life Sciences's PE Ratio without NRI falls into.
Earnings Per Share (EPS) is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.
Earnings Per Share without Non-Recurring Items is the amount of earnings without non-recurring items per outstanding share of the company's stock.
EPS without NRI for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.12
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Emmaus Life Sciences (EMMA) has a EPS without NRI of $-0.12 as of Mar. 2026. EPS without NRI represents per-share earnings excluding one-time charges. View historical data on Emmaus Life Sciences and its competitors. According to the industry distribution chart, Emmaus Life Sciences ranks #486 out of 1172 companies in the Biotechnology industry, placing it in the top 41.5%.
Is Emmaus Life Sciences' EPS without NRI too high?
Emmaus Life Sciences' current EPS without NRI is $-0.12. Based on the distribution chart, Emmaus Life Sciences ranks #486 out of 1172 companies in the Biotechnology industry, which is above the industry midpoint.
How does Emmaus Life Sciences' EPS without NRI compare to PTIX and BZYR?
According to the Biotechnology industry distribution chart, Emmaus Life Sciences ranks #486 out of 1172 companies for EPS without NRI. This puts Emmaus Life Sciences in the upper half of its industry. The industry median EPS without NRI is 16.80. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EPS without NRI for a Biotechnology company?
The median EPS without NRI among Biotechnology companies is 16.80, based on 1,172 companies in the industry. Companies in the top quartile (top 25%) have a EPS without NRI significantly above this median, while those in the bottom quartile fall well below. However, EPS without NRI should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EPS without NRI mean?
A high EPS without NRI can signal that a stock is expensive relative to its fundamentals. EPS without NRI represents per-share earnings excluding one-time charges. View historical data on Emmaus Life Sciences and its competitors. For the Biotechnology industry, the median EPS without NRI is 16.80 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Emmaus Life Sciences's current EPS without NRI is $-0.12. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Emmaus Life Sciences stock overvalued right now?
Based on GuruFocus' analysis, Emmaus Life Sciences (EMMA) is currently considered Fairly Valued. The stock's GF Value™ is $0.01, compared to a current price of $0.01 — trading 2.3% above its estimated fair value. The current EPS without NRI is $-0.12. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EPS without NRI calculated?
EPS without NRI is calculated from a company's financial statements. For Emmaus Life Sciences (EMMA), the current EPS without NRI is $-0.12 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Emmaus Life Sciences Inc is a commercial-stage biopharmaceutical company engaged in the discovery, development, marketing and sales of the Company's product Endari (prescription grade L-glutamine oral powder), to reduce the acute complications of sickle cell disease (SCD) in adult and pediatric patients five years of age and older. Endari is reimbursable by the Centers for Medicare and Medicaid Services, and every state provides coverage for Endari for outpatient prescriptions to all eligible Medicaid enrollees within their state Medicaid programs. Endari is also reimbursable by many commercial payors.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
EMMA has been successfully added to your 